Navigation Links
Lenalidomide Gives New Hope To Chronic Lymphocytic Leukemia Patients

According to a phase II study conducted by Asher Chanan-Khan, MD, Department of Medicine, Roswell Park Cancer Institute (RPCI), patients treated with lenalidomide// for relapsed chronic lymphocytic leukemia (CLL) or diseases that no longer responded to chemotherapy have experienced a major response to the therapy. The results of this study were published in the December 1 issue of the Journal of Clinical Oncology.

"Chronic lymphocytic leukemia is the most common hematologic malignancy in the western hemisphere," according to Dr. Chanan-Khan, "and remains incurable." While several phase II studies have demonstrated improved clinical response to chemotherapy alone, or combined with the monoclonal antibody rituximab, relapse is inevitable and treatment options at that point are limited.

Lenalidomide is a novel immune modulating, non-chemotherapy, cancer drug that is chemically similar to thalidomide, but is more potent in the laboratory and appears to lack some of the more common side effects of thalidomide. Anticancer activity of this agent has been reported in various malignant disorders, including multiple myeloma and myelodysplastic syndrome.

In this phase II study – the first to report clinical activity of lenalidomide in patients with CLL – 45 patients with immunophenotypically diagnosed B-CLL were treated with a daily dose of 25 mg of lenalidomide. Major clinical responses were seen in 21 (47%) of the patients, with four achieving complete response and 17 achieving a partial response; all with a predictable and manageable safety profile. The most common side effects included fatigue, neutropenia and thrombocytopenia.

"Collectively, these data provide strong support for further pursuit of lenalidomide in confirmatory clinical studies that are now open at Roswell Park and other cancer centers in the country," notes Dr. Chanan-Khan.



Source-Eurekalert
SR
'"/>




Page: 1

Related medicine news :

1. Lenalidomide, Granted Approval by FDA to Join Multiple Myeloma Drugs
2. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
3. Gene Therapy Gives Hope For Patients With Muscular Dystrophy
4. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
5. US Doctors Association Gives away $110,000 To NGO’
6. Woman In Coma Gives Birth To Daughter
7. Artificial Heart , Gives Hope For Patients Awaiting a Heart Transplant
8. New Eye Surgery Gives Hope To Short-Sighted
9. Jharkhand Gives Health industry status
10. WHO Gives Its Approval For Bird Flu Test Kit
11. FDA Gives Its Approval For Inhaler
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, ... symposium on “Doping in Sport: How the Culture Might Change,” in ... LLP. The symposium will be held at Pepperdine University in Malibu, California. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... and community for those in the fight against cancer, has produced a seminal ... success. HRA will release top-line findings in a webinar, Defining Compassionate Care ...
(Date:2/23/2017)... RYE, New York (PRWEB) , ... February 23, 2017 , ... ... to evaluate the safety and efficacy of CM-AT in children aged 3-8 with Autism, ... the 30 clinical sites already enrolling children across the United States. , “There ...
(Date:2/22/2017)... ... February 22, 2017 , ... Our high-octane ... overwork even the sharpest brain. , Power On, a mental performance enhancer from ... clocking the brain. Each capsule contains Cognizin® Citicoline, a branded form of the ...
(Date:2/22/2017)... ... ... The National Academy of Certified Care Managers (NACCM) has ... period. NACCM, a nonprofit organization, has provided the premier certification for Care Managers ... to ensure that newly certified professionals are prepared to work effectively on behalf ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017 ... clinical-stage oncology drug development company, announces that it ... Drug Administration (FDA) authorizing the initiation a Phase ... treatment for pancreatic cancer. MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) ... (RIT). MabVax plans to initiate the phase I ...
(Date:2/23/2017)... VANCOUVER, British Columbia , Feb. 23, ... ) today announced its year end 2016 financial results.  ... January 2017, OncoGenex, and Achieve Life Science, Inc., a privately ... into a definitive merger agreement under which OncoGenex will ... the proposed merger, Achieve,s stockholders are expected to own ...
(Date:2/23/2017)... 2017 This report analyzes analyzes the worldwide markets for ... comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America ... provided for the period 2015 through 2022. Also, a six-year ... analytics are derived from primary and secondary research. Company profiles ...
Breaking Medicine Technology: